COVID-19 Has Crystallized the Need for Effective Diagnostics at the Point-of-Need
COVID-19 Has Crystallized the Need for Effective Diagnostics at the Point-of-Need
COVID-19 Has Crystallized the Need for Effective Diagnostics at the Point-of-Need
COVID-19 Has Crystallized the Need for Effective Diagnostics at the Point-of-Need
COVID-19 Has Crystallized the Need for Effective Diagnostics at the Point-of-Need
Enabling Rapid High-Multiplex Immunoassay and Molecular Diagnostics at the Point of Need
Point-of-Care (POC) testing has been the Holy Grail of medical diagnostics for decades. Over the past year, the imperative need to develop novel capabilities that will provide rapid, accessible, and precise immunoassay and molecular testing at any Point-of-Need, has become undeniable.
Proactive Diagnostics' Q-SENS platform meets the essential criteria to fulfill this important goal:
Performance
Sensitivity and specificity equal to or better than a central lab
Small Sample
A finger prick or other tiny bodily fluid sample
Quick Results
Quantitative kinetics detection in under 10 minutes
Simple
Easy to operate, enabling minimally invasive self-testing
Multiplexing
Testing several biomarkers simultaneously in 32 sesnsing-wells
Low Cost
Highly affordable instrument and consumables
Our platform allows for the simultaneous detection of proteins, nucleic acids, and small molecules, unraveling a wide range of use-cases and possibilities. Using its Q-SENS platform, Proactive Diagnostics aims to provide simple and abundant testing spanning multiple novel applications.
The Q-SENS has shown exceptional performance on over 50 different assays, demonstrating its applicability toward a range of health conditions such as cardiovascular disease, infectious disease, oncology, chronic and acute inflammatory markers; and various tests in the veterinary, food safety, and dietary fields.
We envision the Q-SENS becoming the platform of choice for Point-of-Need measuring of biomarkers wherever such capabilities have value.
Proactive Diagnostics will soon announce its roadmap for development. We are open to discussing collaboration and investment opportunities as well as new use-cases and lab-developed-tests. Contact us!